|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A general strategy for bimetallic Pt-based nano-branched structures as highly active and stable oxygen reduction and methanol oxidation bifunctional catalysts显示文摘The morphology and size of Pt-based bimetallic alloys are known to determine their electrocatalytic performance in reactions relevant to fuel cells.Here,we report a general approach for preparing Pt-M(M=Fe,Co and Ni)bimetallic nano-branched structure(NBs)by a simple high temperature solution-phase synthesis.As-prepared Pt-M NBs show a polycrystalline structure and are rich in steps and kinks on the surface,which promote them favorable bifunctional catalytic properties in acidic electrolytes,specifically in terms of the oxygen reduction reaction(ORR)and methanol oxidation reaction(MOR).Specially,Pt-Co NBs/C catalyst shows 6.1 and 5.3 times higher in specific activity(SA)and mass activity(MA)for ORR than state-of-the-art commercial Pt/C catalysts,respectively.Moreover,it exhibits a loss of 4.0%in SA and 14.4%in MA after 10,000 cycles of accelerated durability tests(ADTs)compared with the initial activities.In addition,we also confirmed the superior MOR activity of Pt-Co NBs/C catalyst in acidic electrolytes.For Pt-M NBs with other alloying metals,the ORR and MOR activities are both higher than commercial catalysts and are in the sequence of Pt-Co/C>Pt-Fe/C>Pt-Ni/C>commercial Pt/C(or PtRu/C).The improved activities and durability can benefit from the morphological and compositional effects.This synthesis approach may be applied to develop bifunctional catalysts with enhanced ORR and MOR properties for future fuel cells designs. | Wenjuan Lei Menggang Li Lin He Xun Meng Zijie Mu Yongsheng Yu Frances MRoss Weiwei Yang | 2020 | Nano Research2020，13，3： | 5 |
| 2 | The effect of acute oxidative stress on the ultrastructure of the perfused rat liver 显示文摘 | Cogger V C Mross P E Hosie M J | 2001 | Pharmacol Toxicol2001，89，6： | 1 |
| 3 | Peripheral neuropathy: a persisting challenge in paclitaxel-based re- gimes 显示文摘 | MIELKE S SPARREBOOM A MROSS K | 2006 | Eur J Cancer2006，42，1： | 1 |
| 4 | A phase I dose-escalation study of regorafenib ( BAY 73-4506 ) , an inhibitor of oneogenie, angiogenic, and stromal kinases, in patients with advanced solid tumors 显示文摘 | Mross K Frost A Steinbild S | 2012 | Clin Cancer Res2012，18，9： | 1 |
| 5 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours 显示文摘 | Mross K Drevs J Muller M | 2005 | Eur J Cancer2005，41，9： | 1 |
| 6 | Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion 显示文摘 | RASSMANN I THODTMANN R MROSS M | 1998 | Invest New Drugs1998，16，4： | 1 |
| 7 | Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans 显示文摘 | Mross K Maessen P van der Vijgh W J | 1988 | J Clin Oncol1988，6，3： | 1 |
| 8 | Phase I clinical trial of lobaplatin (D-19466) after in travenous bolus injection 显示文摘 | Fiebig HH Henb H Mross JK | 1994 | Onkologie1994，17，： | 1 |
| 9 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor,in patients with liver metasta- ses from solid tumors显示文摘 | Mross K Drevs J Muller M Medinger M Marine D Hennig J | 2005 | Eur J Cancer2005，41，9： | 1 |
| 10 | Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion 显示文摘 | Rassmann I Th0dtmann R Mross M | 1998 | Invest New Drugs1998，16，4： | 1 |
| 11 | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia 显示文摘 | Sissung TM Mross K Steinberg SM | 2006 | Eur J Cancer2006，42，： | 1 |
| 12 | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia显示文摘 | Sissung TM Mross K Steinberg SM | 2006 | Eur J Cancer2006，42，17： | 1 |
| 13 | Topotecan-A novel topoisomerase I inhibitor: pharmacology and clinical experience显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
| 14 | Phase I study of the angiogenesis inhibitor BIBF1 120 in patients with advanced solid tumors显示文摘 | Mross K Stefanic M Gmehling D | 2010 | Clin Cancer Res2010，16，1： | 1 |
| 15 | PAC fixed dose:pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing显示文摘 | Mross K Hollender N Frost A | 2006 | Onkologie2006，29，10： | 1 |
| 16 | Topotecan-A novel topolsomerase linhibitor:pharmacology and clinical experience显示文摘 | Kollmannsberger C Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
| 17 | Topotecana novel topoisomerase Ⅰ inhibitor:pharmacology and clinical experience 显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，： | 1 |
| 18 | A phase I doseescalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors 显示文摘 | Mross K Frost A Steinbild S | 2012 | Clin Cancer Res2012，18，9： | 1 |
| 19 | A phase I dose-escalation study of BI 811283,an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors 显示文摘 | MROSS K B SCHEULEN M E FROST A | 2010 | J Clin Oncol2010，28，15： | 1 |
| 20 | Topotecan-A novel topoisomerase I inhibitor:pharmacology and clinical experience显示文摘 | Mross K Jakob A | 1999 | Oncology1999，56，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员